Loading
A phase 1/2 trial of temozolomide in colorectal cancer, run by National Cancer Institute (NCI), now recruiting.
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness is a phase 1/2, interventional study registered as NCT05691491 by National Cancer Institute (NCI), with a registry enrolment figure of 42 participants, started 2023-09-28 and due to reach its primary completion in 2027-03-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Temozolomide; Tuvusertib. Conditions listed: Advanced Malignant Solid Neoplasm; Advanced Microsatellite Stable Colorectal Carcinoma; Hematopoietic and Lymphatic System Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Microsatellite Stable Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8. Primary outcome: Dose limiting toxicity and the maximum tolerated dose. Colorectal eligibility wording from the registry: "Patients with MGMT promoter hypermethylated colorectal cancer must be mismatch repair proficient / microsatellite stable". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Temozolomide, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/